Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.
Cervical carcinoma is the predominant cancer among malignancies in women throughout the world, and human papillomavirus (HPV) 16 is the most common agent linked to human cervical carcinoma. The present study was performed to investigate the mechanisms of immune escape in HPV-induced cervical cancer cells. The presence of HPV oncoproteins E6 and E7 in the extracellular fluids of HPV-containing cervical cancer cell lines SiHa and CaSki was demonstrated by ELISA. The effect of HPV 16 oncoproteins E6 and E7 on the production of IFN-gamma by IL-18 was assessed. E6 and E7 proteins reduced IL-18-induced IFN-gamma production in both primary PBMCs and the NK0 cell line. FACS analysis revealed that the viral oncoproteins reduced the binding of IL-18 to its cellular surface receptors on NK0 cells, whereas there was no effect of oncoproteins on IL-1 binding to its surface IL-1 receptors on D10S, a subclone of the murine Th cell D10.G4.1. In vitro pull-down assays also revealed that the viral oncoproteins and IL-18 bound to IL-18R alpha-chain competitively. These results suggest that the extracellular HPV 16 E6 and E7 proteins may inhibit IL-18-induced IFN-gamma production locally in HPV lesions through inhibition of IL-18 binding to its alpha-chain receptor. Down-modulation of IL-18-induced immune responses by HPV oncoproteins may contribute to viral pathogenesis or carcinogenesis.
Lee
S J
SJ
Laboratory of Cellular Biology, Korea Research Institute of Bioscience and Biotechnology, Taejon, Korea.
Cho
Y S
YS
Cho
M C
MC
Shim
J H
JH
Lee
K A
KA
Ko
K K
KK
Choe
Y K
YK
Park
S N
SN
Hoshino
T
T
Kim
S
S
Dinarello
C A
CA
Yoon
D Y
DY
D000276:Adjuvants, Immunologic / Q000378:metabolism / Q000502:physiology*; D001667:Binding, Competitive / Q000276:immunology; D002460:Cell Line; D002474:Cell-Free System / Q000737:chemistry / Q000378:metabolism; D002478:Cells, Cultured; D006801:Humans; D007371:Interferon-gamma / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D007375:Interleukin-1 / Q000378:metabolism; D020382:Interleukin-18 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D053727:Interleukin-18 Receptor alpha Subunit; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D009856:Oncogene Proteins, Viral / Q000378:metabolism / Q000502:physiology*; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D011485:Protein Binding / Q000276:immunology; D018123:Receptors, Interleukin / Q000037:antagonists & inhibitors / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000378:metabolism; D053724:Receptors, Interleukin-18; D012097:Repressor Proteins; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; C068651:E6 protein, Human papillomavirus type 16; C508572:IL18R1 protein, human; D007375:Interleukin-1; D020382:Interleukin-18; D053727:Interleukin-18 Receptor alpha Subunit; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D018123:Receptors, Interleukin; D017472:Receptors, Interleukin-1; D053724:Receptors, Interleukin-18; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; D007371:Interferon-gamma